Equibles does not estimate personal net worth.
Get an email with a short summary when Clover Health Investments, Corp. publishes a filing, an earnings call transcript or a press release.
Get CLOV alertsVivek Garipalli is recorded as Chairman at Clover Health Investments, Corp. (CLOV) since January 1, 2023 and Board Member at Clover Health Investments, Corp. (CLOV) since January 7, 2021. Clover Health Investments, Corp. reported in an 8-K filed August 10, 2022 that Vivek Garipalli was appointed Executive Chairman of the Board, effective January 1, 2023. The proxy statement of Clover Health Investments, Corp. reports total compensation of $389,569,439 for Vivek Garipalli in fiscal 2021. Disclosed compensation is on record for 4 fiscal years. Vivek Garipalli has spoken on 8 earnings calls across 1 company, most recently for Clover Health Investments, Corp. on November 7, 2022. Clover Health Investments, Corp. is classified in the Healthcare Plans industry within the Healthcare sector. Other leadership on record at Clover Health Investments, Corp. includes Andrew Toy (CEO and Board Member), Conrad Wai (CEO and CTO), Jamie L. Reynoso (CEO and COO) and 7 others.
“effective as of January 1, 2023, Vivek Garipalli, the Company's Co-Founder and Chief Executive Officer ("CEO"), will become the Executive Chairman of the Board and leave his position as CEO”
“Our wide network approach powered by Clover Assistant, enabling great primary care, helped deliver a solid set of results for the third quarter.”
“We continue to build upon our strong start to the year, with second-quarter results proving to be another positive step forward. We remain excited about the continued progress against our goals as well as the strategies we are laying out for 2023 and beyond.”
“We are really excited about Clover's start to 2022 and the groundwork we're laying for 2023 and beyond. We believe we can deliver growth well above industry averages, deliver improving margins, and ultimately generate significant positive free cash flow.”
“Just to wrap up, we are excited about our expected improvements for 2022 MA MCR. In addition, we believe we will see another stepwise improvement in MA MCR in 2023.”
“And thanks everyone for joining us today. Clover's wide network and Clover Assistant platform helped drive record growth in the third quarter and was complemented by a significant decrease in MCR.”
2023-01-01–present
2021-01-07–present
Proxy statement
Start not stated–present
Last confirmed April 28, 2026
Start not stated–2022-08-12
Last confirmed by a filing; no departure on record
Healthcare Plans · Healthcare
Chairman, Board Member
2021-01-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Clover Health Investments, Corp. (CLOV) | Chief Executive Officer | — | — |
| 2021 | Clover Health Investments, Corp. (CLOV) | Chief Executive Officer | — | $389,569,439 |
| 2020 | Clover Health Investments, Corp. (CLOV) | Chief Executive Officer | — | — |
| 2019 | Clover Health Investments, Corp. (CLOV) | Chief Executive Officer | — | — |
